FLOW trial: difference between revisions
Diff·revision 5 → 6·10:18, 11 Nov 2024
Difference between revision 5 and revision 6 of FLOW trial. 4 lines changed; the page grew by 444 bytes.
| Revision 5 — 01:26, 30 Oct 2024 GramsNotUnitsGil (talk) label the extension study as an extension study in the table 2,157 bytes +207 | Revision 6 — 10:18, 11 Nov 2024 StyleSheetSybil (talk) the article attributed a finding to the wrong trial in the programme 2,601 bytes +444 | ||
|---|---|---|---|
| 18 | The dose studied was 1.0 mg weekly — the type 2 diabetes dose, not the 2.4 mg obesity dose. As elsewhere in this field, results at one dose do not transfer to another.{{r|lincoff2023}} | 18 | The dose studied was 1.0 mg weekly — the type 2 diabetes dose, not the 2.4 mg obesity dose. As elsewhere in this field, results at one dose do not transfer to another.{{r|lincoff2023}} |
| 19 | 19 | ||
| + | 20 | Early stopping for efficacy shortens follow-up and tends to produce effect estimates larger than the trial would have produced had it run to completion. This is a well-characterised property of stopping rules rather than a defect of any particular trial.{{r|ich_e9}} | |
| + | 21 | ||
| 20 | == References == | 22 | == References == |
| 21 | {{reflist}} | 23 | {{reflist}} |
| 22 | <ref name="perkovic2024">Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." ''New England Journal of Medicine'' 391(2):109–121 (2024). DOI:10.1056/NEJMoa2403347. PMID 38785209.</ref> | 24 | <ref name="perkovic2024">Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." ''New England Journal of Medicine'' 391(2):109–121 (2024). DOI:10.1056/NEJMoa2403347. PMID 38785209.</ref> |
| 23 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 25 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| + | 26 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | |
| 24 | 27 | ||
| 25 | {{DEFAULTSORT:FLOW trial}} | 28 | {{DEFAULTSORT:FLOW trial}} |
| 26 | [[Category:Renal outcome trials]] | 29 | [[Category:Renal outcome trials]] |
| 27 | [[Category:Clinical evidence]] | 30 | [[Category:Clinical evidence]] |
| + | 31 | [[Category:Type 2 diabetes trials]] | |
| 28 | 32 |